Lyell Immunopharma (LYEL) Current Deferred Revenue (2019 - 2022)

Lyell Immunopharma's Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $11.2 million for Q3 2022.

• In Q3 2022, Current Deferred Revenue rose 100.52% year-over-year to $11.2 million; the TTM figure through Sep 2022 stood at $11.2 million (up 100.52% YoY), while the FY2021 annual figure was $5.0 million, down 88.92% from the prior year.
• Current Deferred Revenue came in at $11.2 million for Q3 2022 at Lyell Immunopharma, down from $15.4 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $45.0 million in Q4 2019 to a low of $5.0 million in Q4 2021.
• A 4-year average of $17.7 million and a median of $9.7 million in 2021 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue slumped 88.92% in 2021 and jumped 100.52% in 2022, its largest moves.
• Lyell Immunopharma's Current Deferred Revenue stood at $45.0 million in 2019, then changed by 0.0% to $45.0 million in 2020, then plunged by 88.92% to $5.0 million in 2021, then jumped by 124.36% to $11.2 million in 2022.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $11.2 million, $15.4 million, and $6.2 million for Q3 2022, Q2 2022, and Q1 2022 respectively.

Peer Comparison